Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Pharmacoeconomic Analysis of Influenza Vaccine Prophylaxis Using Trivalent Vaccine in the Conditions of Healthcare in Kazakhstan

View through CrossRef
The primary purpose: To assess the clinical and economic effectiveness of influenza vaccination with population coverage of 40% compared with the absence of vaccination and at 10% current coverage in the health system of the Republic of Kazakhstan. The secondary purpose: To carry out an assessment of clinical and economic effectiveness of influenza vaccination in schoolaged children compared with the absence of vaccination Methods. A decision-making model was developed to assess the economic and clinical effectiveness of influenza vaccination in children and adults. Pharmacoeconomic analysis of influenza vaccine prophylaxis with the use of the trivalent vaccine Grippol® plus in the healthcare environment of Kazakhstan. The creation of the model was based on the description of the influenza progression in vaccinated and unvaccinated children and adults depending on the possible variants of its progression. In addition, to calculate QALY loss, the effect of disease on a patient’s quality of life was taken into account. Results. According to the budget impact analysis results, if school-aged children are vaccinated with coverage of 80%, the total cost stands at 7 140 383 360.87 tenges. In the case of refusal of vaccination among school – aged children, the total treatment costs for children with influenza will account for 8 589 133 135,95 tenges, with expenditures increased by 1 448 749 775,08 tenges. If adults (18 years of age and older) are vaccinated and 10% of the population is covered by immunization, the total cost will be 27 791 126 613.76 and 26 848 387 939.88 tenges, respectively. In the case of non-vaccination in adults, the total costs for the treatment of influenza will be 28 105 372 838,39 tenges, which is higher by 314 246 224,63 tenges than in the case of the population’s vaccination coverage of 10%, and by 1 256 984 898,51 tenges with vaccination coverage of 40%. Conclusion. In general, children and adults’ vaccination is not only a cost-effective but also a cost-saving method of preventing influenza in the health care system of Kazakhstan. Keywords: influenza vaccines, vaccination, clinical effectiveness, cost-effectiveness, cost-utility, children, adults
Title: Pharmacoeconomic Analysis of Influenza Vaccine Prophylaxis Using Trivalent Vaccine in the Conditions of Healthcare in Kazakhstan
Description:
The primary purpose: To assess the clinical and economic effectiveness of influenza vaccination with population coverage of 40% compared with the absence of vaccination and at 10% current coverage in the health system of the Republic of Kazakhstan.
The secondary purpose: To carry out an assessment of clinical and economic effectiveness of influenza vaccination in schoolaged children compared with the absence of vaccination Methods.
A decision-making model was developed to assess the economic and clinical effectiveness of influenza vaccination in children and adults.
Pharmacoeconomic analysis of influenza vaccine prophylaxis with the use of the trivalent vaccine Grippol® plus in the healthcare environment of Kazakhstan.
The creation of the model was based on the description of the influenza progression in vaccinated and unvaccinated children and adults depending on the possible variants of its progression.
In addition, to calculate QALY loss, the effect of disease on a patient’s quality of life was taken into account.
Results.
According to the budget impact analysis results, if school-aged children are vaccinated with coverage of 80%, the total cost stands at 7 140 383 360.
87 tenges.
In the case of refusal of vaccination among school – aged children, the total treatment costs for children with influenza will account for 8 589 133 135,95 tenges, with expenditures increased by 1 448 749 775,08 tenges.
If adults (18 years of age and older) are vaccinated and 10% of the population is covered by immunization, the total cost will be 27 791 126 613.
76 and 26 848 387 939.
88 tenges, respectively.
In the case of non-vaccination in adults, the total costs for the treatment of influenza will be 28 105 372 838,39 tenges, which is higher by 314 246 224,63 tenges than in the case of the population’s vaccination coverage of 10%, and by 1 256 984 898,51 tenges with vaccination coverage of 40%.
Conclusion.
In general, children and adults’ vaccination is not only a cost-effective but also a cost-saving method of preventing influenza in the health care system of Kazakhstan.
Keywords: influenza vaccines, vaccination, clinical effectiveness, cost-effectiveness, cost-utility, children, adults.

Related Results

U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic
U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic
Please cite this paper as: Borders‐Hemphill and Mosholder (2012) U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic. Influenza and...
Modeling the impacts of influenza antiviral prophylaxis strategies in nursing homes
Modeling the impacts of influenza antiviral prophylaxis strategies in nursing homes
Background: Antiviral chemoprophylaxis for influenza is recommended in nursing homes to prevent transmission and severe disease among residents with higher risk of severe influenza...
Perceptions of Telemedicine and Rural Healthcare Access in a Developing Country: A Case Study of Bayelsa State, Nigeria
Perceptions of Telemedicine and Rural Healthcare Access in a Developing Country: A Case Study of Bayelsa State, Nigeria
Abstract Introduction Telemedicine is the remote delivery of healthcare services using information and communication technologies and has gained global recognition as a solution to...
A severe 2017 influenza season dominated by influenza A(H3N2), Victoria, Australia
A severe 2017 influenza season dominated by influenza A(H3N2), Victoria, Australia
Surveillance for influenza-like illness (ILI) and laboratory-confirmed influenza in Victoria, Australia is undertaken jointly by the Victorian Infectious Diseases Reference Laborat...
Comparison of COVID and influenza vaccine hesitancy among clients of the San Antonio Food Bank
Comparison of COVID and influenza vaccine hesitancy among clients of the San Antonio Food Bank
Background The COVID-19 pandemic has continued despite large-scale public health measures. Some people are still hesitant to receive the COVID vaccine. The San Antonio Food Bank (...
Quality of Postoperative Venous Thromboembolism Prophylaxis in Neuro-oncologic Surgery
Quality of Postoperative Venous Thromboembolism Prophylaxis in Neuro-oncologic Surgery
Abstract BACKGROUND: Given the vagaries of published guidelines and the lack of high-quality evidence on the method, timing, and dose of venou...
Specific and Nonspecific Effects of Influenza Vaccines
Specific and Nonspecific Effects of Influenza Vaccines
With the introduction of the influenza vaccine in the official immunization schedule of most countries, several data regarding the efficacy, tolerability, and safety of influenza i...

Back to Top